{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-032187","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2023-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.228220+00:00","generated_at":"2026-06-10T19:01:51.243336+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Avalo extends debt forbearance to Oct 15; grants IP as collateral on $13M loan","bullets":["Forbearance extended from Sept 15 to Oct 15, 2023 under Third Forbearance Agreement.","Outstanding loan principal of $13.07M; MAC default asserted by lenders.","Avalo grants security interest in owned patents and trademarks (First Amendment).","Covenant to maintain at least $3M cash in deposit accounts subject to control agreement.","Lenders have sole discretion to extend forbearance beyond Oct 15."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-032187","json":"https://secwatch.observer/filing/0001628280-23-032187.json","markdown":"https://secwatch.observer/filing/0001628280-23-032187.md","text":"https://secwatch.observer/filing/0001628280-23-032187.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023032187/0001628280-23-032187-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023032187/avtx-20230913.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T19:01:51.243336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1005f6b14b690e1f2546d89383baf47f18e11ee7","claim":"Avalo Therapeutics, Inc. entered into Third Forbearance Agreement with Holders (effective 2023-09-13).","evidence_excerpt":"On September 13, 2023, the Company and the Holders entered into a Third Forbearance Agreement (the “Third Forbearance Agreement”) to, among other things, further extend the forbearance period until October 15, 2023.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023032187/0001628280-23-032187-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Holders"},{"label":"Effective","value":"2023-09-13"}],"fact_type":"material_agreement"},{"claim_id":"adbdeb6eafdc3880e91d23256d0eca344b20ab18","claim":"Avalo Therapeutics, Inc. amended Note Amendment with Holders (effective 2023-09-13).","evidence_excerpt":"the Company agreed to amend the Note to grant to the Holders a security interest in the Company’s owned patents and trademarks (the “Note Amendment”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023032187/0001628280-23-032187-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Holders"},{"label":"Effective","value":"2023-09-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}